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iscussion
r Y. Joseph Woo (Philadelphia, Pa). The authors should be
ongratulated on a great body of work and, as usual, great graphics
rom Toronto. Are venous endothelial cells the same as arterial
ndothelial cells, and are they an adequate surrogate if you are
sing this as a model for allograft vasculopathy and other sorts of
rterial problems?
Dr Danny Ramzy (Toronto, Canada). Thank you for the
uestion. We have actually performed experiments looking at that
uestion. Between human saphenous vein endothelial cells, human
ortic endothelial cells, and human coronary endothelial cells,
nce you pass the first passage, and all experiments are performed
eyond P1, they all behave the same way as ET-1 and other
asoconstrictors and soluble factors. So in terms of using saphe-
ous vein versus aortic cells, the experiments will yield the same
esults.
Dr Mark J. Krasna (Baltimore, Md). Dr Ramzy, could you
ell us a little bit about bosentan? It sounds very exciting. Has it
een used clinically in your group in any other arena yet?
Dr Ramzy. It has been used clinically. It is approved primarily
or primary pulmonary hypertension. It reduces mortality and does
educe pulmonary arterial pressures. It has been used in patients
ith heart failure, with a few of the studies actually showing harm,
ikely due to its induction of hypotension. The patient with heart
ailure died from sudden death, likely from arrhythmia due to
and Cardiovascular Surgery ● Volume 133, Number 5 1145
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CSPypotension. So other than in that setting, it has been used safely
n patients who can be monitored closely or who have adequate
lood pressure. The main problem is the blood pressure.
Dr Krasna. Have either of those groups had any relationship
etween atherosclerosis and bad outcomes and use of bosentan?
Dr. Ramzy. It has been looked at mostly in allograft vascu-
opathy in terms of as a surrogate of atherosclerosis, and it does
educe the burden in terms of amount of disease and the degree of
tenosis.
Dr John G. Byrne (Nashville, Tenn). What do you think are
he principal clinical applications of these findings?
D. Ramzy. The clinical applications are severalfold. In terms of
therosclerosis, the reduction of CRP and ET-1 does reduce both
he atherosclerotic burden and outcomes such as myocardial in-
arction. From our results in terms of protein kinase C, we could
ore specifically target the mechanisms by which CRP results in
therosclerosis and endothelial dysfunction, both in the transplant
etting and in atherosclerosis, and especially following transplan-
ation where there is a high degree of vein restenosis, which, if we146 The Journal of Thoracic and Cardiovascular Surgery ● Mand CRP with bosentan or targeted therapy, we could reduce graft
estenosis and improve survival and quality of life.
Dr Byrne. Are you talking about a vein graft?
Dr Ramzy. Vein graft.
Dr Turki Albacker (Montreal, Canada). Just for my curiosity,
or the clinical application of this study, what do you think about
he level of CRP in a patient posttransplant and do you think it is
igh enough to cause atherosclerosis so you can target it with your
herapy? Thanks.
Dr Ramzy. There are several studies looking at CRP posttrans-
lant. There are a group of patients who do have elevated levels of
RP, so any level above 3 g/mL does result in poor outcome.
here is actually a recent study that shows any levels above 1.06
g/mL result in poor outcome. So a slight increase in CRP is able
o result in worse outcomes in terms of earlier development of
llograft vasculopathy and worse disease, and it has been also
hown if you reduce this level, there is a trend toward improve-
ent. Of course, the concentration we used was 25 g, which is in
he intermediate level. We have done studies previous to that. Any
an modulate basically soluble inflammatory markers like ET-1 level above 3 g/mL does result in endothelial dysfunction.
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